Endothelial cell (EC) dysfunction has a fundamental role in the development of atherosclerosis, which leads to myocardial infarction and stroke. The aim of this study is to investigate the effect of serum from patients with coronary atherosclerotic heart disease (CAD) on endothelial cells and investigate the possible mechanism underlying these effects. Serum from 35 patients with CAD and 35 healthy volunteers was collected. Human umbilical vein endothelial cell (HUVEC) proliferation and apoptosis were assessed by a CCK-8 assay and a flow cytometry assay, respec tively. The synthesis of nitric oxide (NO) and reactive oxygen species (ROS) was measured using the nitrate reduction method and DCFH2-DA staining, respec tively. The prolif eration of HUVECs was inhibited by treatment with serum from CAD patients (P<0.05). Suppression of HUVEC proliferation by CAD serum occurred in a concentration-dependent manner. The synthesis of NO was also reduced in the CAD serum-treated group. Furthermore, the serum from CAD patients increased both apoptosis and intracellular ROS production in HUVECs. Moreover, treatment with tempol antagonized CAD serum-meditated HUVEC injuries. Taken together, these results suggest that HUVEC injury via CAD serum treatment is mediated by ROS production. Tempol may partly reverse this effect by abolishing HUVEC apoptosis.
Introduction
Both genetic and environmental factors cause coronary atherosclerotic heart disease (CAD) [1] [2] [3] . CAD incidence and mortality in China have increased over the last decade [4, 5] . The identified risk factors include hyperlipidemia, hypertension, cigarette smoking, and diabetes mellitus [6] [7] [8] . From a pathological point of view, atherosclerosis induces CAD through endothelial dysfunction [9] [10] [11] [12] . A previous study showed that HUVEC proliferation is reduced when treated with the serum from secondary hyper parathyroidism (SHPT) patients via downregulation of the p-ERK1/2 pathway [13] . Obstructive sleep apnea (OSA) enhances vascular remodeling, vasoconstriction and, ultimately, cardiovascular disease. OSA patients have increased serum inflammatory potential, which induces endothelial activation and dysfunction [14] . Although many studies provide evidence to support the conclusion that endothelial cell injury is harmful to the cardiovascular system [12, 15, 16] , the understanding of the underlying biological mechanisms remains limited.
The level of reactive oxygen species (ROS) increases in the development of atherosclerosis, which stimulates vascular endothelium cell structural damage and dysfunction [11, 17, 18] . Moreover, ROS directly injures endothelial cells and initiates vascular remodeling [19] . Furthermore, endothelial nitric oxide (NO) has a key role in the maintenance of vascular function [20] . Reduced NO levels induces endothelial injury and triggers atherosclerosis development [21, 22] . CAD is also regulated by many intracellular events, including the generation of pro-inflammatory cytokines, which provokes endothelial cell apoptosis and necrosis [10, 23] . Despite these efforts, the molecular mechanisms associating EC injury with CAD risk is poorly understood.
In this study, we investigated whether CAD serum is associated with EC injury and investigated the potential underlying mechanisms.
Materials and methods

Study design and subjects
Informed consent: Written informed consent was obtained from all patients according to the declaration of Helsinki.
Ethical approval: The research related to human use has been complied with all the relevant national regulations, institutional policies and in accordance the tenets of the Helsinki Declaration, and has been approved by the University's local ethics committee. The 35 CAD patient cases and 35 healthy volunteers included in this study were sampled between 2013 and 2016. The healthy control subjects were adults who had annual health examinations at the Shanghai Tongren Hospital from 2013-2016. Cases were ruled out if patients had viral/ drug-induced/autoimmune liver diseases, malignant tumors, renal dysfunction, severe inflammatory diseases or pregnancy. Blood samples were collected through venipuncture, and samples were then centrifuged. The serum specimens were stored at −80 °C until experimental use.
Cell culture
HUVECs were purchased from AllCells (AllCells Technology, Shanghai, China). Cells were grown in complete medium (HUVEC-004, AllCells) in an incubator with 5% CO2 at 37 °C. HUVECs were treated with the serum from patients with CAD for 24 h. HUVECs were treated with the serum from healthy individuals (10%) as a control group.
Cell proliferation assay
The proliferation of cells was assessed by a CCK-8 assay. HUVECs (1×10 4 cells/well) were grown in a 96-well plate overnight. HUVECs were then treated with various concentrations of serum from patients with CAD (5, 10 or 20%) in RPMI-1640 medium for 24 h. To observe the effects of tempol on HUVEC proliferation, cells were seeded with serum from healthy individuals (10%) as a control, 10% CAD serum, or 10% CAD serum with different concentrations of tempol (25, 50 or 100 µM) for 24 h. CCK-8 solution (10 µl) was added to each well for 1 h, and the optical density (OD) at 450 nm was evaluated using a microplate reader.
Cell apoptosis assay
To test the protective function of tempol in CAD seruminduced HUVEC apoptosis, HUVECs (2×10 5 cells/well) were grown in a 6-well plate overnight, and then the cells were treated with 10% CAD serum, 10% CAD serum + tempol (50 or 100 µM) or serum from healthy individuals (10%) as a control in RPMI-1640 medium. After 24 h, cells were washed with cold phosphate-buffered saline (PBS). Cells were then stained using an Annexin V/propidium iodide detection kit (BD Biosciences, San Jose, California). The rate of cell apoptosis was assessed by flow cytometry (FACSCalibur; BD Biosciences, San Jose, CA, USA).
Measurement of intracellular ROS
The DCFH2-DA dye was used to evaluate the production of intracellular ROS. HUVECs (1×10 5 cells/well) were seeded on 24-well plates overnight, and then treated with 10% CAD serum, 10% CAD serum + tempol (50 or 100 µM) or serum from healthy individuals (10%) as a control in RPMI-1640 medium for 24 h. Cells were then incubated with DCFH-DA (10 µM) for 20 min at 37°C in the dark. A fluorescence microscope (Olympus, Tokyo, Japan) was used to detect the ROS production (485 nm excitation; 535 nm emission).
Measurement of NOx level
Cell supernatant was collected, and the level of NOx was assessed by a Griess reaction kit (Life Technologies, Carlsbad, USA) following the manufacturer's protocol.
ELISA assay
Cell supernatant was collected, and the level of stromal cell-derived factor 1 (SDF-1) was assessed by an ELISA kit (Life Technologies, Carlsbad, USA) following the manufacturer's protocol.
Statistical analysis
All experiments were repeated at least three times. Statistical analyses were performed using SPSS 13.0 (SPSS, Inc., Chicago, IL, USA). Values are expressed as the mean ± standard deviation. Multiple compari sons were evaluated using one-way analysis of variance and significant differences between two groups were analyzed using the Student-Newman-Keuls test. In all tests, P<0.05 was considered a statistically significant difference.
Results
Tempol alleviates the inhibitory effect of CAD serum on the proliferation of HUVECs in a concentration-dependent manner
To detect the proliferation of HUVECs, a CCK-8 assay was performed. Compared with the healthy control group, the proliferation of HUVECs in the CAD group decreased significantly (Fig. 1A) . At concentrations of 5-20%, serum of patients with CAD inhibited the proliferation of HUVECs in a dose-dependent manner (P<0.05, Fig. 1A) .
Compared with the CAD only group, the prolif eration of HUVECs was increased in the CAD + tempol group (50 or 100 µM) (Fig. 1B) . The above data indicate that CAD serum reduces the proliferation of HUVECs and that tempol can reverse this effect.
Tempol inhibits apoptosis of HUVECs induced by CAD serum
To detect cell apoptosis rates, an Annexin V/PI assay was performed. Compared with the healthy control group, CAD serum induced apoptosis of HUVECs. The apoptosis rate of the CAD serum-treated group and control group were 18.36±0.82 and 2.93±0.52%, respectively (Fig. 2) . Moreover, the apoptosis rate in the tempol (50 or 100 µM) + CAD group was reduced (Fig. 2) . The above data indicate that CAD serum increased HUVEC apoptosis, and tempol may reverse this effect.
Tempol abrogates the CAD serum-mediated inhibition of NOx production in HUVECs
To detect the NOx level of HUVECs, a Griess assay was performed. Compared with the control group, the production of NOx in the CAD group decreased (Fig. 3 ). However, NOx levels increased in the CAD + tempol group (50 or 100 µM) (P<0.05, Fig. 3 ). The above data indicate that CAD serum decreases HUVEC NOx levels, and tempol can reverse this effect. 
Tempol reduces CAD serum-induced ROS production in HUVECs
To detect ROS production in HUVECs, DCFH2-DA staining was performed. Compared with the control group, DCFH2-DA staining showed that CAD serum treatment increased ROS levels (p < 0.05, Fig. 4 A and B ). Tempol treatment (50 or 100 µM) abolished the CAD serum-induced increased ROS levels in HUVECs (p < 0.05, Fig. 4 A and B) . The above data indicate that CAD serum-induced ROS levels in HUVECs are reversed by tempol treatment.
Tempol reverses SDF-1 levels reduced by CAD serum treatment
To detect SDF-1 levels in HUVECs, an ELISA assay was performed. Compared to healthy controls, SDF-1 levels significantly decreased in the group treated with CAD patient serum (p < 0.05, Fig. 5 ). Tempol treatment (50 or 100 µM) abolished the CAD serum-induced decreased SDF-1 levels in HUVECs (p < 0.05, Fig. 5 ). The above data indicate that CAD serum-induced decreases in SDF-1 levels of HUVECs is reversed by tempol treatment.
Discussion
Multiple factors lead to CAD progression, inducing oxidative stress [24] , inflammatory response [18] , cell apoptosis and vascular remodeling [25] . In this study, we demonstrated that CAD serum inhibits the proliferation of HUVECs in a concentration-dependent manner. CAD serum increases the levels of ROS and cell apoptosis in HUVECs, whereas it decreases the level of NO. Our results also showed that tempol abrogates CAD serum-mediated HUVEC injury, indicating that ROS may play an important role in CAD development.
CAD is a chronic disease that contributes to many pathological processes [26] and is regulated by several signaling pathways [27, 28] . High levels of ROS have severely toxic effects on cells [29] . ROS can stimulate nucleic acid, lipid, and protein biosynthesis, thus delaying cellular metabolism, which leads to cell injury [30] . Tempol is a type of antioxidant that increases both ROS and reactive nitrogen species metabolism. It functions by using catalase activity to increase NO bioavailability [31] . Tempol protects many organ systems, including the nervous system [32] and the cardiovascular system [33, 34] . Tempol has also been used to inhibit radiation-induced injury [35] . Tempol reduced injury in CAD serum-treated HUVECs. Due to its low molecular weight, tempol can permeate cell membranes. Tempol promotes the metabolism of many reactive oxygen species and nitrogen species and decreases oxidative stress. The free electron/radicals of tempol can travel between the nitroxide radical, the decreased hydroxylamine and the oxidized oxoammonium cation. The reaction of tempol with superoxide anion (O2−) produces hydrogen peroxide (H2O2), accounting for tempol's antioxidant action. Tempol was as effective in metabolizing O2 as N-acetylcysteine (NAC); however, NAC can enhance O2− production at lower concentrations [36] . Hence, tempol is regarded as a general-purpose redox cycling therapeutic agent. Our study shows that CAD serum injures HUVECs by inducing ROS generation and cell apoptosis.
SDF-1 is an important factor derived from endothelial cells [37] . The level of SDF-1 in plasma is reduced in patients with ST-elevation myocardial infarction (STEMI), which suggest SDF-1 is a key regulator in patients with acute myocardial infarction [38] . We observed that SDF-1 levels in CAD patients' serum were decreased relative to serum from normal patients. These data suggest that SDF-1 is involved in CAD development. IL1β induces proinflammatory cytokine expression and has been associated with a number of inflammatory diseases, such as coronary atherosclerotic heart disease [14] . IL-6 has been associated with coronary heart disease. Moreover, IL-6 expression increases in response to IL1β induction [39] . The levels of TNFα and CXCL16 increase in coronary atherosclerotic heart disease [40] . Inhibition of TNFα results in many effects including inhibition of IL-1β, IL-6, IL-8 and VEGF expression. Understanding the molecular mechanisms of potential factors contained in CAD serum has potential benefits in CAD prevention.
There were some limitations in the present investigation. First, the number of CAD patients used in this study was relatively small, which may cause statistical errors. Additionally, the healthy control group was not verified by angiography, which would not exclude patients with asymptomatic CAD.
In conclusion, we suggest that ROS generation and apoptosis levels are significantly increased in HUVECs treated with CAD serum. Tempol reverses HUVEC apoptosis and oxidative stress induced by CAD serum treatment. Further investigation may confirm the role of CAD serum in vascular endothelium cells. These results may shed light on our understanding of CAD pathogenesis progression.
